Every 10-Q that Health Catalyst, Inc (HCAT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HCAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCAT filings page.
Health Catalyst, Inc. reported second-quarter and six-month 2026 results showing lower revenue and a large non-cash goodwill charge. Total revenue was $70,487 thousand for the quarter and $141,243 thousand for the first half, down from $80,721 thousand and $160,134 thousand a year earlier, with both technology subscriptions and professional services declining.
Loss from operations was $36,480 thousand in the quarter and $142,957 thousand year-to-date. Net loss reached $40,537 thousand for the quarter and $151,563 thousand, or $2.07 per share, for the first half, largely driven by $122,548 thousand of goodwill impairment in the technology reporting unit. Goodwill fell to $11,101 thousand and stockholders’ equity declined to $100,827 thousand.
Liquidity remained solid, with cash and cash equivalents of $60,589 thousand, short-term investments of $42,850 thousand, and positive operating cash flow of $18,786 thousand in the first half. A term loan of $159,947 thousand remains outstanding. The company agreed to sell its Vitalware business for a base purchase price of $147 million, classifying $91,424 thousand of assets and $12,133 thousand of liabilities as held for sale.
Health Catalyst, Inc. reported weaker first-quarter 2026 results, highlighted by a large non-cash goodwill impairment. Total revenue was $70.8 million, down from $79.4 million a year earlier, with technology revenue at $49.5 million and professional services at $21.3 million.
Operating expenses rose sharply due to a $95.5 million goodwill impairment in the technology reporting unit, driving loss from operations to $106.5 million versus $20.2 million last year. Net loss widened to $111.0 million or $1.53 per share, compared with a $23.7 million loss or $0.35 per share.
Despite the loss, net cash provided by operating activities improved to $18.5 million from $0.3 million, and cash and cash equivalents rose to $59.9 million with short-term investments of $49.0 million. The company carried a variable-rate term loan with $160.4 million principal outstanding and total stockholders’ equity of $138.1 million as of March 31, 2026.
Health Catalyst, Inc. (HCAT) reported Q3 2025 results. Revenue was $76.3 million, essentially flat year over year. Technology revenue rose to $52.1 million while Professional services declined to $24.3 million. Operating loss widened to $17.5 million and net loss was $22.2 million, or $0.32 per share.
Year to date, revenue reached $236.5 million with a net loss of $86.9 million, including a $28.8 million goodwill impairment. Gross costs held steady overall, but operating expenses increased, notably depreciation and amortization at $12.6 million in Q3. Interest and other expense was $4.7 million in Q3, driving a larger pre‑tax loss.
Liquidity contracted: cash and cash equivalents were $40.3 million as of September 30, 2025 versus $249.6 million at year‑end, reflecting $231.9 million of debt repayment and acquisition spending in the nine‑month cash flows. Total assets were $587.1 million and total liabilities $255.2 million. Shares outstanding were 70,730,884 as of November 5, 2025.
Health Catalyst, Inc. reported revenue of $160.1 million for the six months ended June 30, 2025, up from $150.6 million a year earlier, driven by higher recurring technology revenue of $104.4 million (vs. $94.6 million). Despite revenue growth, operating costs and a $28.8 million goodwill impairment contributed to a wider six-month net loss of $64.7 million, or $0.94 per share, compared with a $34.1 million loss a year ago.
Cash and cash equivalents declined sharply to $50.7 million from $249.6 million at year-end, reflecting cash used to settle long-term obligations including the full cash settlement of convertible senior notes and acquisition activity (notably the Upfront acquisition with $80.0 million consideration). Total assets fell to $616.2 million and total liabilities to $268.6 million, leaving stockholders' equity of $347.5 million.